Adenosine Monophosphate Deaminase Deficiency Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 18, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Adenosine Monophosphate Deaminase Deficiency. It connects disease background, epidemiology, a target-mechanism anchor, clinical competition, transaction activity, unmet need and market attractiveness for portfolio and business-development decisions.

Executive assessment

Adenosine Monophosphate Deaminase Deficiency receives a directional strategic score of 73/100. The synthesis combines unmet need (86/100), competitive intensity (40/100, where a higher value means more competition) and market attractiveness (68/100). It is an evidence-organizing framework, not a revenue forecast or medical recommendation.

Disease background and strategic definition

A rare metabolic disorder for which two forms have been described. Lack of activity of the erythrocyte isoform of adenosine monophosphate (AMP) deaminase has been described in subjects with low plasma uric acid levels without obvious clinical relevance and will not be described further. Myoadenylate deaminase deficiency is an inherited disorder of muscular energy metabolism with a lack of AMP deaminase activity in skeletal muscle. It is characterised by exercise-induced muscle pain, cramps and/or early fatigue.

The reproducible entity is Patsnap disease ID 125ca3f4b993404696d993a9de18adc8 with MeSH identifier C538234. Entity-level identifiers matter because rare disorders often carry historical names, gene-defined subtypes and overlapping clinical labels. Strategy teams should lock the intended label and synonym set before comparing epidemiology, trials and deals.

A useful target product profile must specify the treatable phenotype, age and severity range, diagnostic confirmation, prior-therapy requirements, treatment setting, acceptable safety profile and endpoint. In Adenosine Monophosphate Deaminase Deficiency, an overly broad label can inflate the theoretical market while diluting biological signal and making recruitment less predictable.

The care pathway should be mapped from symptom recognition through specialist referral, molecular or biochemical confirmation, treatment initiation and longitudinal monitoring. Diagnostic delay, fragmented referral and limited centers may be as important commercially as drug efficacy. These barriers should appear explicitly in launch and evidence-generation plans.

Epidemiology and disease burden

Epidemiology signal 1: Population-Based Study of the Incidence and Mortality Rate of Acute Aortic Dissection

the current incidence, early fatality, and mortality rates of AAD with the medical care system in our jurisdictional medical area by reporting actual epidemiological informa- tion on AAD in a geographically well-defined, medium- sized, rural city. Although recent studies have suggested that the incidence of AAD is increasing,4–7 the actual incidence and mortality rate of AAD are not well known. Previous studies on AAD have been hospital based or restricted to specialist centers, or have been retrospective studies using registry data.1,2,11 These studies may have underestimated the incidence and mortality due to incomplete inclusion of deaths before hospital arrival.14 Howard et al3 reported the incidence of AAD was 6.0 per 100,000 inhabitants per year in their previous Oxfordshire population-based study. However, the ability of that data to capture the cause of death before arrival at hospital may have been limited because of the low rate of postmortem examinations.3 In the present study, we reported an approximately double age-standardized mean annual incidence of AAD (11.4 per 100,000 inhabitants per year). Moreover, in the present study, the rate of Ai or autopsy for patients who were dead on arrival at hospital was 82.2% during the study period. Furthermore, as in previous population-based studies,3–7,15 we showed that increasing age was significantly associated with an increased incidence of AAD. The increased inci- dence of AAD in the present study may be attributed to the older mean age of patients and the higher rates of postmortem examinations. It is presumed that

Review the underlying epidemiology source

Epidemiology signal 2: Heart Disease and Stroke Statistics—2023 Update Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association

• According to administrative claims data of US Medicare fee-for-service beneficiaries ≥65 years of age in 2014, AD/ADRD prevalence was 11.5% with a higher prevalence in females (12.2%) com- pared with males (8.6%).10 AD/ADRD prevalence increased with age (65–74 years of age, 3.6%; 75–84 years of age, 13.6%; and ≥85 years of age, 34.6%). The prevalence of AD/ADRD was 13.8% in Black individuals, 12.2% in Hispanic individuals, 10.3% in NH White individuals, 9.1% in American Indian and Alaska Native individuals, and 8.4% in Asian and Pacific Islander individuals. Alzheimer Disease • Results of a multistate model using biomarker data and US population predictions show that ≈3.7 mil- lion Americans ≥30 years of age had clinical AD in 2017, and this number is projected to increase to 9.3 million by 2060.11 • More than 95% of those with probable AD had multiple or mixed pathologies, and only 3.1% of those with probable AD had only AD pathology according to updated data from 1078 consecu- tive deceased individuals with autopsy (mean age at death, 89 years; 32% male) from the ROS and the MAP.4 Vascular Dementia • More than 80% of those with probable AD had vascular pathology (defined as microinfarcts, mod- erate to severe atherosclerosis, arteriolosclerosis, and cerebral amyloid angiopathy), and merely 4.9% of those with probable AD had vascular pathology only according to data from the ROS and the MAP.4 Incidence Dementia • In 2017, AD/ADRD had the fifth leading inci- dence rate of neurological disorders in the United States according to GBD Study data.9 The US age-standardized inc

Review the underlying epidemiology source

Epidemiology signal 3: Epidemiology of Neuralgic Amyotrophy—A RetrospectiveAnalysis of Data From a Large German HealthInsurance Company Epidemiology of Neuralgic Amyotrophy—A Retrospective Analysis of Data From a Large German Health Insurance Company

The pathophysiology of the disease—as it is currently under- stood—is based on the combination of a genetic predisposition, an immunological trigger [3] and a mechanical trigger (e.g., prolonged physical activity in the shoulder girdle area) [4]. The latter factor leads to increased permeability of the blood-­nerve barrier via microtraumatization of the nerves, allowing cellu- lar or humoral components of the immune system to reach the endoneural space and triggering an autoimmune-­inflammatory process [5]. Overall, the disease has been found to have a significantly worse outcome and greater economic significance than previ- ously assumed. Up to 25% of employees who develop NA are unable to return to their previous work in the long term; for the Netherlands, with approximately 7.1 million employees, the annual costs caused by lost production have been calculated at USD 40,000,000 [6]. Earlier studies estimated the annual inci- dence to be between 1 and 3 cases per 100,000 individuals [7, 8]. However, a more recent, prospective study reported a 30 to 100 times higher incidence, approximately 100 cases per 100,000 people [6]. The available epidemiological data is limited, especially data from cohorts with high case numbers. In the German context, in particular, there is a lack of current figures on NA, yet these figures are crucial for well-­informed discussions and the devel- opment of needs-­based diagnostic and therapeutic strategies. Therefore, the present study aimed to provide incidence and prevalence figures by analyzing the epidemiological data of a German health insu

Review the underlying epidemiology source

Epidemiology should be converted into an addressable-patient funnel: total affected population → diagnosed patients → clinically eligible segment → treated patients → realistically accessible patients. Incidence, point prevalence and lifetime prevalence are not interchangeable; estimates from different age bands, case definitions or health systems should not be pooled without adjustment.

For Adenosine Monophosphate Deaminase Deficiency, the next population work should quantify diagnostic yield, severity distribution, referral-center concentration, treatment penetration and survival or progression. Sensitivity analyses should show how each assumption affects recruitment, peak penetration and budget impact. A transparent range is more useful than a single precise-looking estimate built from incompatible sources.

Unmet need and patient-value thesis

The unmet-need thesis must name the failure that a new intervention will change: irreversible progression, incomplete disease control, treatment-limiting toxicity, burdensome administration, weak durability, delayed diagnosis or lack of options for a biomarker-defined subgroup. High disease severity alone does not prove that a clinical program can demonstrate benefit.

A strong Adenosine Monophosphate Deaminase Deficiency strategy connects mechanism to a pre-specified responder population and an endpoint understood by regulators, clinicians, patients and payers. It also tests whether benefit can be measured within a feasible time horizon and whether natural-history variability can be controlled. Patient-reported outcomes, functional measures and health-resource use may add value when standard biomarkers do not capture daily burden.

The recommended first development population is the narrowest segment that remains operationally recruitable and has the clearest biological rationale. Expansion should follow evidence of target engagement and response rather than precede it. This sequencing protects capital and improves the interpretability of early clinical results.

Target mechanism anchor: PTH1R

G protein-coupled receptor for parathyroid hormone (PTH) and for parathyroid hormone-related peptide (PTHLH) (PubMed:10913300, PubMed:18375760, PubMed:19674967, PubMed:27160269, PubMed:30975883, PubMed:35932760, PubMed:8397094). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (cAMP) (PubMed:30975883, PubMed:35932760). PTH1R is coupled to G(s) G alpha proteins and mediates activation of adenylate cyclase activity (PubMed:20172855, PubMed:30975883, PubMed:35932760). PTHLH dissociates from PTH1R more rapidly than PTH; as consequence, the cAMP response induced by PTHLH decays faster than the response induced by PTH (PubMed:35932760).

The mechanism anchor for this landscape is PTH1R. It is a pathway hypothesis, not an assertion that every patient is target-dependent. Translational diligence should establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream pathway modulation and a therapeutic window in the intended population.

Critical experiments include orthogonal engagement assays, dose–response work in disease-relevant systems, biomarker qualification, evaluation of compensatory pathways and explicit on-target and off-target safety testing. Human evidence should receive more weight than model-only findings. Negative results in related mechanisms should be analyzed for exposure, population, endpoint and biological lessons.

A go decision requires a chain of evidence: target present in the relevant tissue; modulation achieved at tolerated exposure; pharmacodynamic change observed; and that change plausibly connected to clinical benefit. If any link is missing, the program should remain at a lower investment gate.

Clinical development and competition

The focused query returned 1 registered studies overall. Recent sampled records include:

• NCT06092346 — A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders; status Recruiting; phase Not Applicable; sponsor National Human Genome Research Institute; enrollment 999.

Trial count is not equivalent to the number of competing products. Observational studies, natural-history cohorts and multiple trials from one asset can distort the headline. Each record should be normalized by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact disease subtype.

Competitive strategy must compare against the likely standard of care at launch, not only today's treatment. Potential whitespace may come from earlier intervention, genotype selection, improved durability, reduced monitoring, safer chronic use, simpler administration or a rational combination. The differentiation claim should be visible in protocol design and prospectively defined analyses.

Recruitment risk deserves its own workstream in Adenosine Monophosphate Deaminase Deficiency. Site density, diagnostic testing, competing protocols, travel burden and screen-failure rates should inform country and center selection. Natural-history data can reduce uncertainty but should not substitute for a well-controlled efficacy strategy when endpoints are variable.

Transactions and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This negative signal can mean limited partnering momentum, a broader deal label or asset-level transactions not indexed to the exact indication. Target- and asset-based comparable searches should be added before valuation.

Headline deal value is rarely a clean comparable. Upfront payments, milestones, royalties, options, bundled assets, platform rights and geographic scope must be separated. A defensible comparable set matches indication, target, modality, stage and territory, then explains every remaining difference.

Partner readiness depends on a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical plan, intellectual-property position, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Outreach is most effective around a credible catalyst that can retire a material portion of risk.

For Adenosine Monophosphate Deaminase Deficiency, direct transaction scarcity can create whitespace, but it can also signal weak validation or a difficult commercial model. Broader pathway deals are useful only when their scientific and economic relevance is made explicit. Avoid treating unrelated rare-disease transactions as interchangeable simply because both populations are small.

Market attractiveness and access

Market attractiveness is shaped by diagnosis infrastructure, specialist concentration, treatment duration, administration setting, payer controls, current alternatives, monitoring burden and geographic reimbursement. A rare population can still be attractive when identification is reliable, centers are concentrated and effect size is meaningful; a larger population can disappoint when diagnosis and access are fragmented.

The commercial model should include conservative, base and upside scenarios. Key variables are diagnosed prevalence, eligible share, launch timing, competing approvals, net price, persistence and achievable penetration. Each assumption should have a source, date and range. Scenario outputs should be updated when new epidemiology, trial or transaction evidence arrives.

Payer research should begin before pivotal design so comparator, endpoint and follow-up choices support reimbursement as well as approval. Evidence plans may need quality-of-life, caregiver burden, hospital use, diagnostic costs or productivity outcomes. The strongest value proposition ties clinical benefit to outcomes that matter across stakeholders.

Risks and decision gates

• Disease-definition risk: confirm a consistently diagnosed and recruitable population.
• Biology risk: demonstrate that PTH1R is relevant in the selected phenotype.
• Translation risk: connect engagement to a biomarker and clinically meaningful endpoint.
• Competition risk: refresh the landscape before every investment gate.
• Operational risk: validate sites, testing capacity and screen-failure assumptions.
• Commercial risk: test access, pricing and adoption with clinicians and payers.
• Data risk: interpret zero-result searches as prompts for broader queries, not proof of absence.

Recommended gates are: confirm population and natural history; validate mechanism in human evidence; define a differentiated target product profile; establish early proof of mechanism; and scale only after clinical signal, operational feasibility and commercial logic converge. Every gate needs pre-agreed stop criteria.

Strategic recommendation

Adenosine Monophosphate Deaminase Deficiency merits continued, milestone-based evaluation. The opportunity is strongest if a biomarker or phenotype can identify patients with coherent biology, if PTH1R modulation is measurable, and if the proposed benefit is meaningful against future care. The current evidence supports further diligence rather than an unconditional investment decision.

The near-term business-development objective is to build a partner-ready thesis explaining the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scorecard provides a common language for comparison, while the attached evidence and explicit gaps preserve analytical traceability.

Methodology and source note

This report was assembled on August 18, 2026 using Patsnap MCP tools in sequence: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and may change as databases update. Counts are directional search outputs, not clinical, regulatory or investment advice.

Ranking weights are 40% unmet need, 25% inverse competitive intensity and 35% market attractiveness. Inputs include disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Before a transaction or portfolio commitment, rerun searches with synonyms, disease roll-ups, gene or pathway names and asset filters.

Conclusion

The central question for Adenosine Monophosphate Deaminase Deficiency is whether a biologically grounded therapy can produce a material patient benefit in an identifiable population and remain differentiated through launch. The current evidence supplies a structured starting point; the gaps define the next diligence plan. Connected MCP searches make the thesis refreshable as disease knowledge, trials and transactions evolve.